

11 November 2015

Reply to Reviewer 00722050

Paper no. 21488

Dear Reviewer,

Many thanks for your valuable advice and the opportunity to revise the paper 21488 for resubmission.

In the enclosed version I have responded to the reviewer's suggestions regarding the following points:

- 1) The Chapter 6 concerning clinical trials was corrected and supplemented.
- 2) The sentence "*Many of modalities used in this treatment strategy, such as cryotherapy, high intensity focused ultrasounds (HIFU), local and stereotactic radiotherapy, laser ablation or hormonal therapy [3, 5], reveal severe urinary morbidity and variable efficiency [3, 26-30]*", was removed.
- 3) The definition of logP was added.

However, I would like to clarify following questions:

- 1) The aim of this article was presentation of vascular targeted photodynamic therapy in context of its clinical application. Detailed description of PDT action and its molecular and cellular mechanism (autophagy etc.) goes beyond the framework of this article.
- 2) Information on molecular parameters of photosensitizers used in VTP are interesting rather for researchers and not for clinicians to whom this article is addressed. Therefore, such information was in this article only mentioned.
- 3) The adverse effects of VTP in the LPCa treatment was described in detail in the Chapter 6.

I have looking forward to your comments on the revised manuscript.

Yours sincerely,  
dr. Andrzej M. Bugaj

Answer to chief editor:

Dear Dr. Ma,

Thank you of your information on completed review of my article "Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight" (no. 21488) sent for publication in World Journal of Methodology.

Please find enclosed the corrected version of my article after language polishing, revised and supplemented. The changes were yellow highlighted.

I am sorry for any inconvenience I may have caused.

Yours sincerely,  
dr. Andrzej M. Bugaj